ACA
BCRX icon

Avoro Capital Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

Avoro Capital Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,250,000
Closed -$9.49M – 36
2025
Q3 		$9.49M Sell
1,250,000
-3,250,000
-72% -$27.1M 0.12% 28
2025
Q2 		$40.3M Sell
4,500,000
-4,200,000
-48% -$39.1M 0.71% 25
2025
Q1 		$65.3M Sell
8,700,000
-3,165,000
-27% -$25.5M 1.02% 20
2024
Q4 		$89.2M Hold
11,865,000
– – 1.26% 21
2024
Q3 		$90.2M Sell
11,865,000
-705,000
-6% -$5.36M 1.31% 19
2024
Q2 		$77.7M Sell
12,570,000
-480,000
-4% -$2.65M 1.03% 24
2024
Q1 		$66.3M Hold
13,050,000
– – 0.77% 28
2023
Q4 		$78.2M Buy
13,050,000
+1,500,000
+13% +$8.69M 1.08% 21
2023
Q3 		$81.8M Sell
11,550,000
-505,000
-4% -$3.63M 1.28% 17
2023
Q2 		$84.9M Buy
12,055,000
+1,635,000
+16% +$13.1M 1.15% 20
2023
Q1 		$86.9M Buy
10,420,000
+1,370,000
+15% +$13.2M 1.29% 19
2022
Q4 		$104M Hold
9,050,000
– – 1.55% 16
2022
Q3 		$114M Buy
9,050,000
+2,550,000
+39% +$32.8M 2.11% 13
2022
Q2 		$68.8M Buy
6,500,000
+4,625,000
+247% +$47.7M 1.36% 17
2022
Q1 		$30.5M Buy
+1,875,000
New +$30.1M 0.56% 28
2018
Q1 		– Sell
-340,821
Closed -$1.67M – 57
2017
Q4 		$1.67M Sell
340,821
-1,437,704
-81% -$6.96M 0.11% 43
2017
Q3 		$9.32M Sell
1,778,525
-175,000
-9% -$896K 0.72% 27
2017
Q2 		$10.9M Buy
1,953,525
+350,524
+22% +$2.14M 1.37% 21
2017
Q1 		$13.5M Sell
1,603,001
-28,501
-2% -$198K 1.72% 20
2016
Q4 		$10.3M Buy
1,631,502
+252,100
+18% +$1.31M 2.09% 19
2016
Q3 		$6.08M Buy
+1,379,402
New +$5.51M 1.07% 25

Other funds holding BCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Avoro Capital Advisors's BCRX Position: Q4 2025 in Review

Avoro Capital Advisors sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2025, closing a stake of 1,250,000 shares — an estimated $9.49M sold.

Avoro Capital Advisors first reported a position in BCRX in Q3 2016 and held it in 21 quarters. The position peaked at $114M in Q3 2022. 272 funds tracked by Wall St. Rank hold BCRX as of Q4 2025.

  • Avoro Capital Advisors reported no remaining BioCryst Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Avoro Capital Advisors sold 1,250,000 BioCryst Pharmaceuticals shares in Q4 2025, an estimated $9.49M.
  • Avoro Capital Advisors first reported a position in BioCryst Pharmaceuticals in Q3 2016 and held it in 21 quarters.
  • Avoro Capital Advisors's BioCryst Pharmaceuticals position peaked at $114M in Q3 2022.
  • 272 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2025.

Based on Avoro Capital Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.